Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-002264-24 | EudraCT Number | EudraCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tiotropium + olodaterol low dose | Experimental | Once daily 2 puffs solution for inhalation Respimat |
|
| tiotropium + olodaterol high dose | Experimental | Once daily 2 puffs solution for inhalation Respimat |
|
| tiotropium | Active Comparator | Once daily 2 puffs solution for inhalation Respimat |
|
| placebo | Placebo Comparator | Once daily 2 puffs solution for inhalation Respimat |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| olodaterol | Drug | fixed dose combination |
|
| Measure | Description | Time Frame |
|---|---|---|
| FEV1 AUC0-3h Response | Forced expiratory volume in one second (FEV1) Area under the curve (AUC) 0-3h was calculated as the area under the FEV1-time curve from 0 to 3h post-dose using the trapezoidal rule, divided by the duration (3h) to report in litres. FEV1 AUC0-3h response was defined as FEV1 AUC0-3h minus baseline FEV1. The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | baseline and 12 weeks |
| Trough FEV1 Response (Change From Baseline) | Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FEV1 measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FEV1 response was defines as trough FEV1 minus baseline FEV1. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | baseline and 12 weeks |
| St. George's Respiratory Questionnaire (SGRQ) Total Score Based on Data From This Individual Study | The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life). The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | 12 weeks treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Trough Forced Vital Capacity (FVC) Response (Change From Baseline) | Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FVC measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FVC response was defined as trough FVC minus baseline FVC. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1237.26.10620 Boehringer Ingelheim Investigational Site | Jasper | Alabama | United States | |||
| 1237.26.10618 Boehringer Ingelheim Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32671684 | Derived | Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naive to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. Adv Ther. 2020 Oct;37(10):4175-4189. doi: 10.1007/s12325-020-01411-0. Epub 2020 Jul 15. | |
| 32462607 |
Not provided
Not provided
Not provided
809 patients were randomised and treated.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Once daily 2 puffs solution of placebo for inhalation with Respimat |
| FG001 | Tiotropium 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium for inhalation with Respimat |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| tiotropium | Drug | fixed dose combination |
|
| placebo | Drug |
|
| St. George's Respiratory Questionnaire (SGRQ) Total Score Based on Combined Dataset From This Study and the Replicate Study NCT01964352 |
This endpoint was evaluated after combining the data from this and the replicate study NCT01964352 as specified in the analysis plan. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life). The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. |
| 12 weeks treatment |
| baseline and 12 weeks |
| TDI Focal Score Based on Data From This Individual Study | Mahler Transitional Dyspnoea Index (TDI) focal score was performed to measure the effect of the treatment on patients' dyspnoea.(Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9). The adjusted mean (SE) are obtained from fitting an MMRM model including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | 12 weeks |
| TDI Focal Score Based on Combined Dataset From This Study and the Replicate Study NCT01964352 | This endpoint was evaluated after combining the data from this and the replicate study NCT01964352 as specified in the analysis plan. Mahler Transitional Dyspnoea Index (TDI) focal score was performed to measure the effect of the treatment on patients' dyspnoea.(Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9). The adjusted mean (SE) are obtained from fitting an MMRM model including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | 12 weeks |
| FVC AUC0-3h Response (Change From Baseline) | The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | baseline and 12 weeks |
| Stamford |
| Connecticut |
| United States |
| 1237.26.10619 Boehringer Ingelheim Investigational Site | Clearwater | Florida | United States |
| 1237.26.10614 Boehringer Ingelheim Investigational Site | Tampa | Florida | United States |
| 1237.26.10616 Boehringer Ingelheim Investigational Site | Duluth | Georgia | United States |
| 1237.26.10613 Boehringer Ingelheim Investigational Site | St Louis | Missouri | United States |
| 1237.26.10615 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | United States |
| 1237.26.10603 Boehringer Ingelheim Investigational Site | Columbus | Ohio | United States |
| 1237.26.10621 Boehringer Ingelheim Investigational Site | Dayton | Ohio | United States |
| 1237.26.10612 Boehringer Ingelheim Investigational Site | Toledo | Ohio | United States |
| 1237.26.10605 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | United States |
| 1237.26.10606 Boehringer Ingelheim Investigational Site | Medford | Oregon | United States |
| 1237.26.10610 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | United States |
| 1237.26.10607 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | United States |
| 1237.26.10617 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | United States |
| 1237.26.10608 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | United States |
| 1237.26.10604 Boehringer Ingelheim Investigational Site | Union | South Carolina | United States |
| 1237.26.10609 Boehringer Ingelheim Investigational Site | Boerne | Texas | United States |
| 1237.26.10602 Boehringer Ingelheim Investigational Site | San Antonio | Texas | United States |
| 1237.26.10601 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | United States |
| 1237.26.61004 Boehringer Ingelheim Investigational Site | Concord | New South Wales | Australia |
| 1237.26.61002 Boehringer Ingelheim Investigational Site | Daw Park | South Australia | Australia |
| 1237.26.61003 Boehringer Ingelheim Investigational Site | Toorak Gardens | South Australia | Australia |
| 1237.26.61007 Boehringer Ingelheim Investigational Site | Woodville | South Australia | Australia |
| 1237.26.61005 Boehringer Ingelheim Investigational Site | Murdoch | Western Australia | Australia |
| 1237.26.61001 Boehringer Ingelheim Investigational Site | Nedlands | Western Australia | Australia |
| 1237.26.43004 Boehringer Ingelheim Investigational Site | Feldbach | Austria |
| 1237.26.43002 Boehringer Ingelheim Investigational Site | Grieskirchen | Austria |
| 1237.26.43003 Boehringer Ingelheim Investigational Site | Linz | Austria |
| 1237.26.43006 Boehringer Ingelheim Investigational Site | Linz | Austria |
| 1237.26.43001 Boehringer Ingelheim Investigational Site | Thalheim bei Wels | Austria |
| 1237.26.11605 Boehringer Ingelheim Investigational Site | Moncton | New Brunswick | Canada |
| 1237.26.11609 Boehringer Ingelheim Investigational Site | Courtice | Ontario | Canada |
| 1237.26.11608 Boehringer Ingelheim Investigational Site | Sarnia | Ontario | Canada |
| 1237.26.11606 Boehringer Ingelheim Investigational Site | Toronto | Ontario | Canada |
| 1237.26.11607 Boehringer Ingelheim Investigational Site | Toronto | Ontario | Canada |
| 1237.26.11601 Boehringer Ingelheim Investigational Site | Windsor | Ontario | Canada |
| 1237.26.11611 Boehringer Ingelheim Investigational Site | Mirabel | Quebec | Canada |
| 1237.26.11602 Boehringer Ingelheim Investigational Site | Point Claire | Quebec | Canada |
| 1237.26.11603 Boehringer Ingelheim Investigational Site | Sherbrooke | Quebec | Canada |
| 1237.26.49610 Boehringer Ingelheim Investigational Site | Bamberg | Germany |
| 1237.26.49611 Boehringer Ingelheim Investigational Site | Berlin | Germany |
| 1237.26.49616 Boehringer Ingelheim Investigational Site | Berlin | Germany |
| 1237.26.49609 Boehringer Ingelheim Investigational Site | Bochum | Germany |
| 1237.26.49607 Boehringer Ingelheim Investigational Site | Dresden | Germany |
| 1237.26.49612 Boehringer Ingelheim Investigational Site | Frankfurt | Germany |
| 1237.26.49615 Boehringer Ingelheim Investigational Site | Halberstadt | Germany |
| 1237.26.49606 Boehringer Ingelheim Investigational Site | Hamburg | Germany |
| 1237.26.49608 Boehringer Ingelheim Investigational Site | Hanover | Germany |
| 1237.26.49603 Boehringer Ingelheim Investigational Site | Hettstedt | Germany |
| 1237.26.49604 Boehringer Ingelheim Investigational Site | Leipzig | Germany |
| 1237.26.49605 Boehringer Ingelheim Investigational Site | Leipzig | Germany |
| 1237.26.49601 Boehringer Ingelheim Investigational Site | Lübeck | Germany |
| 1237.26.49602 Boehringer Ingelheim Investigational Site | Rüdersdorf | Germany |
| 1237.26.49614 Boehringer Ingelheim Investigational Site | Schwerin | Germany |
| 1237.26.49613 Boehringer Ingelheim Investigational Site | Wiesloch | Germany |
| 1237.26.30005 Boehringer Ingelheim Investigational Site | Athens | Greece |
| 1237.26.30002 Boehringer Ingelheim Investigational Site | Heraklion | Greece |
| 1237.26.30001 Boehringer Ingelheim Investigational Site | Nafplion | Greece |
| 1237.26.30004 Boehringer Ingelheim Investigational Site | Serres | Greece |
| 1237.26.30003 Boehringer Ingelheim Investigational Site | Thessaloniki | Greece |
| 1237.26.64001 Boehringer Ingelheim Investigational Site | Greenlane East Auckland NZ | New Zealand |
| 1237.26.47003 Boehringer Ingelheim Investigational Site | Hamar | Norway |
| 1237.26.47001 Boehringer Ingelheim Investigational Site | Hønefoss | Norway |
| 1237.26.47002 Boehringer Ingelheim Investigational Site | Kløfta | Norway |
| 1237.26.47004 Boehringer Ingelheim Investigational Site | Lierskogen | Norway |
| 1237.26.42103 Boehringer Ingelheim Investigational Site | Bardejov | Slovakia |
| 1237.26.42104 Boehringer Ingelheim Investigational Site | Humenné | Slovakia |
| 1237.26.42102 Boehringer Ingelheim Investigational Site | Spišská Nová Ves | Slovakia |
| 1237.26.42101 Boehringer Ingelheim Investigational Site | Vyšné Hágy | Slovakia |
| 1237.26.27601 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1237.26.27602 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1237.26.27604 Boehringer Ingelheim Investigational Site | Cape Town | South Africa |
| 1237.26.27605 Boehringer Ingelheim Investigational Site | Durban | South Africa |
| 1237.26.46004 Boehringer Ingelheim Investigational Site | Höllviken | Sweden |
| 1237.26.46001 Boehringer Ingelheim Investigational Site | Lund | Sweden |
| 1237.26.46002 Boehringer Ingelheim Investigational Site | Stockholm | Sweden |
| 1237.26.46003 Boehringer Ingelheim Investigational Site | Uddevalla | Sweden |
| Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(R) and OTEMTO(R) Studies. Adv Ther. 2020 Aug;37(8):3485-3499. doi: 10.1007/s12325-020-01373-3. Epub 2020 May 27. |
| 27316465 | Derived | Singh D, Gaga M, Schmidt O, Bjermer L, Gronke L, Voss F, Ferguson GT. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies. Respir Res. 2016 Jun 18;17(1):73. doi: 10.1186/s12931-016-0387-7. |
| 26320402 | Derived | Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015 Oct;109(10):1312-9. doi: 10.1016/j.rmed.2015.08.002. Epub 2015 Aug 12. |
| FG002 | Tiotropium 2.5 μg+ Olodaterol 5 μg | Once daily 2 puffs solution of 1.25 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
| FG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Once daily 2 puffs solution of placebo for inhalation with Respimat |
| BG001 | Tiotropium 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium for inhalation with Respimat |
| BG002 | Tiotropium 2.5 μg+ Olodaterol 5 μg | Once daily 2 puffs solution of 1.25 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
| BG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | FEV1 AUC0-3h Response | Forced expiratory volume in one second (FEV1) Area under the curve (AUC) 0-3h was calculated as the area under the FEV1-time curve from 0 to 3h post-dose using the trapezoidal rule, divided by the duration (3h) to report in litres. FEV1 AUC0-3h response was defined as FEV1 AUC0-3h minus baseline FEV1. The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from the Full Analysis Set (FAS): This patient set included all randomized and treated patients who had a baseline and at least one postbaseline measurement for any of the primary efficacy endpoints. | Posted | Mean | Standard Error | L | baseline and 12 weeks |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Trough FEV1 Response (Change From Baseline) | Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FEV1 measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FEV1 response was defines as trough FEV1 minus baseline FEV1. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS | Posted | Mean | Standard Error | L | baseline and 12 weeks |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | St. George's Respiratory Questionnaire (SGRQ) Total Score Based on Data From This Individual Study | The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life). The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS | Posted | Mean | Standard Error | units on a scale | 12 weeks treatment |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | St. George's Respiratory Questionnaire (SGRQ) Total Score Based on Combined Dataset From This Study and the Replicate Study NCT01964352 | This endpoint was evaluated after combining the data from this and the replicate study NCT01964352 as specified in the analysis plan. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life). The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS after combining the data from this and the replicate study NCT01964352 | Posted | Mean | Standard Error | units on a scale | 12 weeks treatment |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Trough Forced Vital Capacity (FVC) Response (Change From Baseline) | Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FVC measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FVC response was defined as trough FVC minus baseline FVC. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS | Posted | Mean | Standard Error | L | baseline and 12 weeks |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | TDI Focal Score Based on Data From This Individual Study | Mahler Transitional Dyspnoea Index (TDI) focal score was performed to measure the effect of the treatment on patients' dyspnoea.(Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9). The adjusted mean (SE) are obtained from fitting an MMRM model including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS | Posted | Mean | Standard Error | Units on a scale | 12 weeks |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | TDI Focal Score Based on Combined Dataset From This Study and the Replicate Study NCT01964352 | This endpoint was evaluated after combining the data from this and the replicate study NCT01964352 as specified in the analysis plan. Mahler Transitional Dyspnoea Index (TDI) focal score was performed to measure the effect of the treatment on patients' dyspnoea.(Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9). The adjusted mean (SE) are obtained from fitting an MMRM model including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS after combining the data from this and the replicate study NCT01964352 | Posted | Mean | Standard Error | Units on a scale | 12 weeks |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | FVC AUC0-3h Response (Change From Baseline) | The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom. | Patients from FAS | Posted | Mean | Standard Error | L | baseline and 12 weeks |
|
up to 112 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Once daily 2 puffs solution of placebo for inhalation with Respimat | 4 | 202 | 34 | 202 | ||
| EG001 | Tiotropium 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium for inhalation with Respimat | 12 | 203 | 15 | 203 | ||
| EG002 | Tiotropium 2.5 μg +Olodaterol 5 μg | Once daily 2 puffs solution of 1.25 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. | 4 | 202 | 25 | 202 | ||
| EG003 | Tiotropium 5 μg +Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. | 6 | 202 | 14 | 202 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Acute coronary syndrome | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Supraventricular tachycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Blindness | Eye disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Large intestine polyp | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Umbilical hernia | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment |
| |
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.1 | Systematic Assessment |
| |
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.1 | Systematic Assessment |
| |
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.1 | Systematic Assessment |
| |
| Carotid artery stenosis | Nervous system disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Alcoholism | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 17.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment |
|
Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim, Call Center | Boehringer Ingelheim | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C549647 | olodaterol |
| D000069447 | Tiotropium Bromide |
| ID | Term |
|---|---|
| D012602 | Scopolamine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
| D009930 | Organic Chemicals |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
Not provided
Not provided
| Male |
|
| <0.0001 |
| Mean Difference (Final Values) |
| 0.105 |
| Standard Error of the Mean |
| 0.019 |
| 2-Sided |
| 95 |
| 0.069 |
| 0.141 |
| No |
| Superiority or Other |
| Mixed Effects Model for Repeated Measure | <0.0001 | Mean Difference (Final Values) | 0.284 | Standard Error of the Mean | 0.020 | 2-Sided | 95 | 0.246 | 0.323 | No | Superiority or Other |
| Mixed Effects Model for Repeated Measure | <0.0001 | Mean Difference (Final Values) | 0.091 | Standard Error of the Mean | 0.019 | 2-Sided | 95 | 0.053 | 0.128 | No | Superiority or Other |
| Mixed Effects Model for Repeated Measure | <0.0001 | Mean Difference (Final Values) | 0.194 | Standard Error of the Mean | 0.019 | 2-Sided | 95 | 0.156 | 0.232 | No | Superiority or Other |
| Mixed Effects Model for Repeated Measure | 0.4499 | Mean Difference (Final Values) | 0.014 | Standard Error of the Mean | 0.019 | 2-Sided | 95 | -0.023 | 0.051 | No | Superiority or Other |
| OG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
| OG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
| OG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
| OG003 |
| Tiotropium 5 μg + Olodaterol 5 μg |
Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
Once daily 2 puffs solution of 1.25 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
| OG003 | Tiotropium 5 μg + Olodaterol 5 μg | Once daily 2 puffs solution of 2.5 μg tiotropium / 2.5 μg olodaterol for inhalation with Respimat. |
|
|
|
|
|
|